A shift in the balance between two lipids – cholesterol and sphingomyelin – makes hybrid epithelial-mesenchymal cancer cells less responsive to certain chemotherapy drugs.
“We’ve never had such an in-depth map of the CD1 lipidome available,” said Patricia Barral, an immunologist at King’s College London who was not involved with the work. “It will enable us to start ...